Arterial blood gas analysis PPT for the cardio student.
Very important topic and concepts that should be clear to those who are dealing with ICU patients
The Norwood procedure is the first of three surgeries required to treat single-ventricle conditions such as hypoplastic left heart syndrome (HLHS). Because the left side of the heart can’t be fixed, the series of surgeries rebuilds other parts of the heart.
The Norwood procedure is performed in the baby’s first or second week of life.to redirect the blood flow.
Three goals for the Norwood procedure:
1, Build a new aorta.
2, Direct blood from the right ventricle through the new aorta and on to the rest of the body.
3, Direct the right ventricle to pump blood to the lungs until the next surgery.
The Norwood procedure is the first of three surgeries required to treat single-ventricle conditions such as hypoplastic left heart syndrome (HLHS). Because the left side of the heart can’t be fixed, the series of surgeries rebuilds other parts of the heart.
The Norwood procedure is performed in the baby’s first or second week of life.to redirect the blood flow.
Three goals for the Norwood procedure:
1, Build a new aorta.
2, Direct blood from the right ventricle through the new aorta and on to the rest of the body.
3, Direct the right ventricle to pump blood to the lungs until the next surgery.
BCC4: Michael Parr on ICU - Surviving Trauma GuidelinesSMACC Conference
Michael Parr, director of Liverpool ICU in Australia, speaks about "Surviving Trauma Guidelines". He does so through the use of an interesting case of a patient admitted to ICU following a MVA. This educational podcast was recorded at BCC4.
This presentation will help physiotherapy students for their theory as well as practical purpose for measuring the exercise tolerance level of the individual.
This presentation includes maximal and sub maximal exercise testing with it's VO2 max formula
This presentation gives brief description of the treadmill test, am-strand cycle ergo-meter test, 6MWT, symptom limited testing, shuttle walk test
How to manage a case of acute exacerbation of COPD according to GOLD guidelines. Sincere thanks to Dr. Amardeep Toppo who has prepared most of this presentation.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
BCC4: Michael Parr on ICU - Surviving Trauma GuidelinesSMACC Conference
Michael Parr, director of Liverpool ICU in Australia, speaks about "Surviving Trauma Guidelines". He does so through the use of an interesting case of a patient admitted to ICU following a MVA. This educational podcast was recorded at BCC4.
This presentation will help physiotherapy students for their theory as well as practical purpose for measuring the exercise tolerance level of the individual.
This presentation includes maximal and sub maximal exercise testing with it's VO2 max formula
This presentation gives brief description of the treadmill test, am-strand cycle ergo-meter test, 6MWT, symptom limited testing, shuttle walk test
How to manage a case of acute exacerbation of COPD according to GOLD guidelines. Sincere thanks to Dr. Amardeep Toppo who has prepared most of this presentation.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
2. ABG ( Arterial blood gass)
◦ ABG – Arterial blood gases, which are present in the blood is called arterial blood gases for eg
CO2, O2, SPo2. PH etc.
◦ An arterial-blood gas (ABG) test measures the amounts of arterial gases, such as Oxygen,
carbondioxide, PH, bicarbonate and saturated oxygen .
◦ An ABG test requires that a small volume of blood be drawn from the radial artery because it is
easily accessible, can be compressed to control bleeding . The selection of which radial artery
to draw from is based on the outcome of an Allen's test.
◦ Other arteries for withdrawIng of blood are – Dorsalis pedis, Femoral and brachial artery.
4. ◦ Check for any contraindications to arterial blood gas sampling:
◦ Absolute contraindications: peripheral vascular disease in the limb, cellulitis surrounding the
site or arteriovenous fistula.
◦ Relative contraindications: impaired coagulation (e.g. anticoagulation therapy, liver disease,
low platelets <50).
◦ Check if the patient has an allergy to local anaesthetic (e.g. lidocaine).
5. ◦ Position the patient so that they are sitting comfortably, ideally with their wrist supported by a
pillow. If a bed is available, the patient can lay down for the procedure (this is sometimes
preferable, particularly if the patient is prone to vasovagal syncope).
◦ Ask the patient if they have any pain before continuing with the clinical procedure.
◦ Then choose the appropriate artery, if radial artery will be choosen then need to perform a
simple test for better outcome.
6. ◦ Allen test is a medical sign used in physical examination of arterial blood flow to the
hands.
◦ The original test proposed by Allen is performed as follows:
◦ The patient is asked to clench both fists tightly for 1 minute at the same time.
◦ Pressure is applied over both radial arteries simultaneously so as to occlude them.
◦ The patient then opens the fingers of both hands rapidly, and the examiner compares
the colour of both. The initial pallor should be replaced quickly by rubor.
7.
8. Indication
◦ 1) Respiratory failure. And assess its severity.
◦ 2) To monitor the patient on ventilator and assist weaning.
◦ 3) To Measure the acid-base level in the blood of people who are have heart
failure, kidney failure, uncontrolled diabetes, sleep disorders, severe infections, or
after a drug overdose.
◦ 4) Severe metabolic disturbance e.g. diabetic ketoacidosis
◦ 5) All critically ill patients.
9. Parameters for ABG test
◦ 1) PH 7.35 to 7.45 in which from 7.35 to 7.39 is acidic and from 7.40 to 7.45 basic.
◦ 2) PCO2 35 to 45 mmhg
◦ 3) PO2 80 to 100 mmhg
◦ 4) SPO2 >90%
◦ 5) Bicarbonates 22 to 28 mEq/l
10. ◦ Main 3 functions which are checked during ABG test
◦ - Respiratory function PCO2
◦ - metabolic function HCO3
◦ - Acid base balance PH.
11. Main 4 disorders which will be found
during ABG analysis
◦ 1 Respiratory Acidosis
◦ 2 Respiratory Alklosis
◦ 3 Metabolic Acidosis
◦ 4 Metabolic Alklosis
12. Interpretation.
◦ Rules
◦ If PH HCO3 PCO2
◦ Compensated Abnormal Abnormal / normal Abnormal /
Normal
◦ Partly compensated Abnormal Abnormal Abnormal
◦ Fully compensated Normal Abnormal Abnormal.
13. Henderson Hasselbach Equation
◦ PH ~ HCO3/ PCO2.
◦ HCO3 is metabolic component
◦ PCO2 is Respiratory component
◦ Acc. To this equation always consider abnormal values for eg. If the Hco3 is abnoraml and
the pco2 is normal then we will say that the Metabolic acidosis or alkalosis.
14. 4 Step method
◦ Step 1 – Use PH to determine the Acidosis and Akalosis
◦ Normal value of PH id 7.35 to 7.45 If ph is > 7.45 is alkalosis
◦ If ph value <7.35 Acidosis.
◦ Step 2 Interpretation of Equation and analysis Is either uncompensated, partly or fully compensated.
◦ Step 3 Determine respiratory effect
◦ Normal value 35 to 45 mmhg if > 45 acidosis ( low ph) , <35 alkalosis high ph)
◦ Or
◦ Determine Metabolic effect
◦ Normal value 22 to 28 mEq/l If > 28 Alkalosis , <22 acidosis.
◦ Step 4 If both the metabolic and respiratory factors are abnormal then minus the abnormal value
from the normal value and considered greater one .
15. Solve Example
◦ PH = 7.46 Ab.
◦ Pco2 = 44.4 normal
◦ HCO3 = 31.1 Ab.
◦ Pco2 113.2 Ab.
◦ Step 1 Alkalosis
◦ Step 2 Interpretation of formula PH~HCO3/PCO2
◦ Uncompensated.
◦ Step 3 Metabolic
◦ Conclusion = Uncompensated metabolic alkalosis Hyperoxemia. ( 1)
21. ◦ Arterial blood gas (ABG) values alone don't provide enough information to diagnose a
problem. For example, they can't tell whether low levels are caused by lung or heart
problems. Arterial blood gas values are most helpful when they are reviewed with
other examinations and tests.
◦ An ABG test is often done for a person who is in the hospital because of severe injury
or illness. The test can measure how well the person's lungs and kidneys are working
and how well the body is using energy.
◦ An ABG test may be most useful when a person's breathing rate is increased or
decreased or when the person has very high blood sugar (glucose) levels, a severe
infection, or heart failure.
22.
23. Extubation
◦ Removal of tracheal tube or tracheotomy tube from the trachea is termed as
Extubation.
24. Creteria for extubation
◦ Approach
◦ Determine disease resolution and consider other factors
◦ Identify candidates for spontaneous breathing trial
◦ Perform spontaneous breathing trial
◦ Identify candidates for extubation
◦ Extubation and post-extubation care.
25. DETERMINE DISEASE
RESOLUTION
◦ Begins with the resolution of respiratory failure and/or the disease that prompted initiation of
mechanical ventilation
◦ Criteria to define disease resolution are not defined
◦ A systemic approach emphasising objective surrogate markers of recovery
◦ Adequate oxygenation and gas exchange
◦ PaO2 >60mmHg on FiO2 <40%
◦ PEEP 5–8cmH2O
◦ CXR stable or improving
26. ◦ absent or only low dose vasopressors/inotropes
◦ SBP>90mmHg.
◦ Stable cardiac rhythm
◦ No tacycardia
◦ No evidence of myocardial ischemia
◦ GCS>8 equivalent, some able to follow commands, some neither.
◦ No continuous sedative infusion or neuromuscular blockade
◦ no significant weakness (e.g. can lift head off pillow, raise arms in air for 15 seconds, clap
hands)
◦ pain controlled
27. No significant acidosis
◦ No electrolytes disturbance .
◦ adequate fluid status (not overloaded)
◦ abdominal pain/ distention controlled
◦ tolerating feeds
◦ Adequate hemoglobin
◦ Sepsis control.
28. Identify candidates for spontaneous
breathing trial
◦ Spontaneous breathing trials (SBT) are used to identify patients who are likely to fail
liberation from mechanical ventilation.
◦ SBT is a test for determining readiness to breathe without a ventilator”
◦ Ideally, during an SBT we want to observe the patient under conditions of respiratory
load that would simulate those following extubation.
◦ IDENTIFICATION OF PATIENTS SUITABLE FOR SBT
◦ Patients that pass the following daily ‘wean screen’ should undergo SBT:
◦ lung disease is stable/ resolving
◦ low FiO2 (< 50%) and PEEP (< 5-8cmH2O) requirement
◦ haemodynamic stability .
◦ able to initiate spontaneous breaths (good neuromuscular function)
◦ This indicates patients suitable for a spontaneous breathing trial, those who pass also
to be assessed for extubation.
29. Method
◦ SBT involves the following steps:
◦ It be conducted while the patient is still connected to the ventilator circuit.
◦ When using the ventilator a PS of 5 – 7 cmH2O and 1-5 cmH20 PEEP (so called ‘minimal
ventilator settings’) will overcome increased work of breathing through the circuit (i.e. ETT)
◦ If still on the ventilator the patient should have ‘minimal ventilator settings”
◦ Initial trial should last 30 – 120 minutes
◦ If patient is not tolerate this, then Test will be negative (But)
◦ 80% of patients who tolerate this time can be permanently removed from the ventilator
30. PERFORM SPONTANEOUS
BREATHING TRIAL
◦ IDENTIFY PATIENTS READY FOR TRIAL OF EXTUBATION
◦ Key questions
◦ Awake or easily rousable?
◦ Able to follow commands?
◦ Minimal volume of respiratory secretions?
◦ Intact gag and cough reflex to prevent aspiration? (absent gag is normal in many
people)
◦ Consider a cuff leak test to check for laryngeal oedema:
◦ Laryngeal edema reported in as many as 40% of prolonged intubations
◦ 5% patients experience severe upper airway obstruction following extubation
◦ can be detected by ‘cuff leak’ test
31. Cuff leak test
◦ The cuff leak test is used to predict risk of post-extubation stridor in intubated patients
◦ Use and interpretation of the test needs to take into account the overall context of the patient’s condition and the
management implications.
◦ Procedure
◦ Suction endotracheal and oral secretions and set the ventilator in the assist control mode with the patient receiving
volume-cycled ventilation
◦ With the cuff inflated, record displayed inspiratory and expiratory tidal volumes to see whether these are similar
◦ Deflate the cuff
◦ Directly record the expiratory tidal volume over the next six breathing cycles as the expiratory tidal volume will
reach a plateau value after a few cycles
◦ Average the three lowest values
◦ The difference between the inspiratory tidal volume (measured before the cuff was deflated) and the averaged
expiratory tidal volume (after cuff deflation) is the cuff leak volume
32. ◦ failed cuff-leak test
◦ was defined as a leak volume of less than 110 mL, or 15.5%
◦ of exhaled volume before cuff deflation.
◦ EXTUBATION AND POST-EXTUBATION CARE
◦ Monitor closely for Laryngospasm and Post-extubation stridor — reintubation is not
always need
◦ Consider high flow nasal prongs or non-invasive ventilation to treat or prevent post-
extubation respiratory failure
33. Extubation failure
◦ primary types of failure.
“the inability to tolerate removal of the translaryngeal tube.
“ liberation failure is used to refer to the inability to tolerate spontaneous ventilation without
mechanical support.
Causes of failure
1) Laryngospasm
2) Postobstructive Pulmonary Edema
3) Laryngeal Edema
4) Airway injury.
34. Treatment of Extubation Failure
◦ The onset of respiratory distress following extubation
◦ should alert the clinician that the patient is failing extuba-
◦ tion. Hypercapnia, hypoxia, and abdominal breathing are
◦ all signs that re-intubation may be necessary. Severe post-
◦ extubation stridor and an inability to manage secretions
◦ are additional indications for re-intubation.
◦ Patients who fail extubation have an increased mortality
◦ rate compared with patients who are successfully extu-
◦ bated on the first attempt
35. or patients who fail their first
◦ breathing trial are not extubated. NIV has not been shown to reduce
◦ the rates of re-intubation, and it can increase mortality by
◦ delaying re-intubation.